Cue Biopharma, a Boston-based clinical-stage biopharmaceutical company, develops biologic drugs for immune system modulation to treat cancers and autoimmune disorders. Its key candidates include CUE-101 for HPV-positive HNSCC and CUE-102 for Wilms' Tumor 1 protein.
Cue Biopharma (CUE) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cue Biopharma's actual EPS was -$0.17, beating the estimate of -$0.19 per share, resulting in a 12.55% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
